BRIGHT MINDS BIOSCIENCES INC.
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
DRUG | NDAQ
Overview
Corporate Details
- ISIN(s):
- CA10919W1086
- LEI:
- Country:
- United States of America
- Address:
- 19 VESTRY STREET, 10013 NEW YORK
- Website:
- https://brightmindsbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for severe neurological and psychiatric disorders. The company utilizes a proprietary chemistry platform to create next-generation serotonergic drugs, specifically highly selective 5-HT2A and 5-HT2C agonists, designed to regulate serotonin pathways in the central nervous system. Its therapeutic pipeline of new chemical entities targets conditions such as epilepsy, depression, and pain. The company's lead candidate, BMB-101, is in clinical development for treating various forms of epilepsy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all BRIGHT MINDS BIOSCIENCES INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BRIGHT MINDS BIOSCIENCES INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BRIGHT MINDS BIOSCIENCES INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
